Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H31N3O2.ClH |
Molecular Weight | 405.961 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCCCN1CCC(CNC(=O)C2=C3OCCCN3C4=C2C=CC=C4)CC1
InChI
InChIKey=UABVCZHWRUGYSR-UHFFFAOYSA-N
InChI=1S/C22H31N3O2.ClH/c1-2-3-11-24-13-9-17(10-14-24)16-23-21(26)20-18-7-4-5-8-19(18)25-12-6-15-27-22(20)25;/h4-5,7-8,17H,2-3,6,9-16H2,1H3,(H,23,26);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C22H31N3O2 |
Molecular Weight | 369.5004 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Piboserod (SB 207266) is a selective 5-HT(4) receptor, antagonist. The 5-HT4 receptor antagonists are thought to antagonize both the ability of serotonin to sensitize the peristaltic reflex and 5-HT-induced defecation, at least in animal studies. As 5-HT4 receptors are present in human atrial cells and when stimulated may cause atrial arrhythmias, piboserod was under investigation in clinical trials for atrial fibrillation. In addition, GlaxoSmithKline studied the drug for the management of irritable bowel syndrome. Nevertheless, development both indications had been discontinued. Piboserod has successfully passed phase II clinical trials for the treatment of patients with congestive heart failure.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q13639|||Q9NY73 Gene ID: 3360.0 Gene Symbol: HTR4 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15902472 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19567409
Piboserod 80 mg for 24 weeks including 4 weeks up titration.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8762092
The pharmacology of piboserod (SB 207266) has been evaluated in vitro in the guinea-pig distal colon longitudinal muscle myenteric plexus (LMMP). SB 207266 is a highly potent antagonist of 5-HT-evoked, cholinergically-mediated contractions in the guinea-pig distal colon. Low concentrations (0.1-10 nM) produced a parallel shift to the right of the concentration-effect curve (apparent pA2 10.6 +/- 0.1) with no significant effect on the maximum response. With higher concentrations of SB 207266 (30 nM and above) the maximum response to 5-HT was reduced. SB 207266 is not an irreversible antagonist since the effects of the compound were reversible upon washing of the tissue.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:33:12 GMT 2023
by
admin
on
Fri Dec 15 15:33:12 GMT 2023
|
Record UNII |
61Z0VMM0AJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66885
Created by
admin on Fri Dec 15 15:33:12 GMT 2023 , Edited by admin on Fri Dec 15 15:33:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
LL-64
Created by
admin on Fri Dec 15 15:33:12 GMT 2023 , Edited by admin on Fri Dec 15 15:33:12 GMT 2023
|
PRIMARY | |||
|
CHEMBL356359
Created by
admin on Fri Dec 15 15:33:12 GMT 2023 , Edited by admin on Fri Dec 15 15:33:12 GMT 2023
|
PRIMARY | |||
|
177335
Created by
admin on Fri Dec 15 15:33:12 GMT 2023 , Edited by admin on Fri Dec 15 15:33:12 GMT 2023
|
PRIMARY | |||
|
178273-87-5
Created by
admin on Fri Dec 15 15:33:12 GMT 2023 , Edited by admin on Fri Dec 15 15:33:12 GMT 2023
|
PRIMARY | |||
|
DTXSID40170453
Created by
admin on Fri Dec 15 15:33:12 GMT 2023 , Edited by admin on Fri Dec 15 15:33:12 GMT 2023
|
PRIMARY | |||
|
m8775
Created by
admin on Fri Dec 15 15:33:12 GMT 2023 , Edited by admin on Fri Dec 15 15:33:12 GMT 2023
|
PRIMARY | Merck Index | ||
|
C73841
Created by
admin on Fri Dec 15 15:33:12 GMT 2023 , Edited by admin on Fri Dec 15 15:33:12 GMT 2023
|
PRIMARY | |||
|
61Z0VMM0AJ
Created by
admin on Fri Dec 15 15:33:12 GMT 2023 , Edited by admin on Fri Dec 15 15:33:12 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |